Market Place
Sourcing Support
All News #Library
Biotech
Transgene Finishes Patient Randomization In Phase 2 Trial
14 Apr 2026 //
PHARMIWEB
Transgene, NEC Partner To Advance Personalized Cancer Vaccine
08 Apr 2026 //
INDPHARMAPOST
Transgene Presents Individualized Neoantigen Vaccine TG4050
26 Mar 2026 //
PHARMIWEB
Transgene Bolsters Board With Cancer Immunotherapy Experts
26 Jan 2026 //
PHARMIWEB
Genvivo To Unveil GEN2, Cancer Immunotherapy Phase 1 Trial
07 Nov 2025 //
GLOBENEWSWIRE
Transgene Unveils VacDesignR for Tailored Cancer Vaccines
06 Nov 2025 //
PHARMIWEB
Transgene & BioInvent’s BT-001 Shows Strong Antitumor Activity
20 Oct 2025 //
ACCESSWIRE
Transgene, Bioinvent To Unveil BT-001, Oncolytic Virus Data
13 Oct 2025 //
ACCESSWIRE
Transgene To Unveil Immunological Data From TG4050, Cancer
06 Oct 2025 //
PHARMAWEB
Transgene, BioInvent to Share BT-001 Oncolytic Virus Data at ESMO
28 Jul 2025 //
ACCESSWIRE
Transgene`s viral cancer vaccine flunks midphase test
15 Oct 2024 //
FIERCE PHARMA
Transgene & BioInvent - First Patient Treated in Phase I Trial Assessing BT-001
10 Oct 2023 //
BUSINESSWIRE
Transgene and NEC Present New Data on TG4050
06 Jun 2023 //
BUSINESSWIRE
Transgene Presents Immunological Data Demonstrating that TG4001
05 Jun 2023 //
BUSINESSWIRE
Transgene, NEC present positive data from TG4050 at AACR 2023 meeting
20 Apr 2023 //
PHARMABIZ
New Data Showing that Transgene and NEC’s Individualized Cancer Vaccine TG4050
18 Apr 2023 //
BUSINESSWIRE
Transgene - Preclinical Results Showing TG6050, a Novel Oncolytic Virus
17 Apr 2023 //
BUSINESSWIRE
Transgene to Host KOL Webinar on TG405
04 Apr 2023 //
BUSINESSWIRE
Transgene Receives Approval to Start a Phase I Trial of TG6050
06 Jan 2023 //
BUSINESSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.